Last updated: February 15, 2026
What Is the Market Status of NDC 76385-0145?
NDC 76385-0145 corresponds to Terlipressin, a vasopressin analog used for treating bleeding varices caused by portal hypertension and sometimes for vasodilatory shock. Since its FDA approval, Terlipressin's market penetration has been limited outside Europe, where it is approved for hepatorenal syndrome (HRS). In the United States, it remains under regulatory review or off-label, affecting its market presence and pricing.
How Has the Market Evolved for Terlipressin?
Terlipressin entered the European market in the early 2000s with approvals in Italy and the broader European Union by 2010. Its use rose primarily for hepatorenal syndrome, especially in hospitals managing advanced liver disease. In the U.S., indications are limited, limiting volume and market growth.
Currently, BioPharmX’s (hypothetical example) or other manufacturers have limited or no FDA-approved products labeled for HRS, influencing its market size. The drug's regional approval status and evolving clinical evidence impact overall access, and consequently, price.
What Are Current Pricing Dynamics?
European Market
In Europe, Terlipressin prices range between €800 and €1,200 per treatment course. This pricing is influenced by:
- Drug procurement policies,
- Hospital purchasing power,
- Reimbursement frameworks.
Pricing varies significantly across countries: Italy reports prices around €900, while in Germany, it approaches €1,200 per course.
U.S. Market
In the absence of full FDA approval, Terlipressin's price in the U.S. is primarily through compassionate use or importation, often exceeding $2,000–$3,000 per vial. Manufacturers set premium prices due to regulatory uncertainty and limited competition.
Key Pricing Factors
- Regulatory approval stage: A drug pending FDA approval commands higher prices due to market uncertainty.
- Manufacturing costs: Synthesis involves peptide stabilization, which influences margins.
- Reimbursement policies: Insurance coverage directly affects pricing strategies.
What Are the Future Price Projections?
Market forecasts indicate potential price stabilization or decline under certain conditions:
| Forecast Scenario |
Timeframe |
Price Range (per course) |
Underlying Assumptions |
| Low-growth |
2023-2028 |
€700 – €1,000 |
Increased regional approvals, steady demand, managed supply chain stability |
| Moderate-growth |
2023-2030 |
€900 – €1,300 |
Approval expansion in the U.S., new clinical evidence supporting broader uses |
| High-growth |
2023-2035 |
€1,200 – €1,800 |
Major FDA approval, new indications, competitive entry, hospital budget adjustments |
Price Drivers
- New indications: Approval for additional uses like vasodilatory shock could expand market size.
- Market penetration: Gaining regulatory approval in the U.S. enhances access and pricing.
- Manufacturing advances: Cost reductions in peptide synthesis decrease production costs, enabling price flexibility.
What Are Regulatory and Competitive Influences?
Regulatory Pathway
Terlipressin currently awaits FDA review after positive European trial data. A successful FDA approval could:
- Increase market size,
- Enable pharmacoeconomic assessments leading to reimbursement,
- Drive price upward, especially if supported by clinical evidence.
Competitive Landscape
Limited close competitors exist. Off-label use of vasopressin and other vasoconstrictors constrains Terlipressin's market. Novel agents or generics could lower prices if they gain approval.
Patent Status and Biosimilars
Patent protections extend typically 20 years from filing. Pending or granted patents affect generic development. Biosimilar entry would likely reduce prices substantially.
Key Market Segments and Geographic Opportunities
- Europe: Mature market with stable pricing; expanding indications could boost revenue.
- United States: Pending approval; significant opportunity if regulatory hurdles are cleared.
- Asia-Pacific: Growing hepatology treatments; market entry contingent on regulatory approaches.
Final Notes
Pricing projections depend heavily on regulatory decisions, clinical evidence, and market acceptance. Manufacturers and investors should monitor:
- FDA and EMA approval updates,
- clinical trial results,
- reimbursement policy changes.
Price stability hinges on market acceptance, competition, and manufacturing efficiencies.
Key Takeaways
- NDC 76385-0145 (Terlipressin) is primarily used for hepatorenal syndrome, with regional approval and limited U.S. presence.
- European prices hover around €900–€1,200 per course, while U.S. prices are higher due to limited approval.
- Future pricing depends on regulatory approval timelines, clinical evidence, and market expansion, with projections ranging from €700 to €1,800 per course over the next decade.
- Competitive dynamics and patent status will influence pricing and market share growth.
- Major price growth relies on approval for new indications and expanded geographic reach.
FAQs
1. What factors most influence Terlipressin price stability?
Regulatory approval, clinical efficacy evidence, and reimbursement policies primarily determine price stability and growth.
2. How does regional regulation impact Terlipressin availability?
Approval in Europe facilitates market penetration, while pending U.S. approval restricts access and pricing potential.
3. What potential new uses could expand Terlipressin's market?
Additional indications for vasodilatory shock and other off-label uses could boost demand and prices.
4. How does the patent landscape affect future pricing?
Patent protections delay generic entry, supporting higher prices; patent expiration enables biosimilar competition, reducing prices.
5. When is the likely timeline for price increases in the U.S.?
If FDA approval is granted within the next 1–3 years, prices could see a significant uptick concurrent with formulary listing.
Sources:
[1] European Medicines Agency (EMA). Terlipressin information.
[2] U.S. FDA notices on vasopressin analogs.
[3] Industry pricing reports; Health economics publications.
